- Bristol Myers Squibb will invest approximately $2.3 billion to build a modular, multi-modal manufacturing campus in Houston, Texas, supporting production of small molecules, biologics, and antibody-drug conjugates.
- The facility is expected to create nearly 500 permanent jobs and forms part of the company’s $40 billion U.S. investment commitment over five years.
Bristol Myers Squibb has selected Houston, Texas, as the location for a new approximately $2.3 billion multi-modal manufacturing campus designed to support the production of next-generation medicines. The approximately 600,000-square-foot facility will manufacture small molecules, biologics, and antibody-drug conjugates across multiple disease areas, supporting drug product and finished goods manufacturing from late-stage development through commercial launch. The campus is expected to create nearly 500 permanent jobs.
The manufacturing campus will feature a modular design that allows production capacity to be expanded or reconfigured as pipeline and commercial requirements evolve. According to the company, the facility will incorporate advanced digital capabilities and automation to support manufacturing flexibility, quality, and supply reliability. The investment is part of Bristol Myers Squibb’s previously announced $40 billion commitment to invest in research and development, technology, and domestic manufacturing in the United States over five years.
“This investment reflects our confidence in America’s continued leadership in biopharmaceutical innovation. As part of our $40 billion commitment to the United States, we’re building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs.”
Christopher Boerner, Ph.D., Board Chair and CEO of Bristol Myers Squibb
The company said the Houston site was selected following an evaluation of multiple locations, citing workforce availability, infrastructure, incentives, and the local business environment. Construction is expected to generate approximately 2,000 construction and indirect jobs between 2027 and 2030, while the completed facility will support long-term manufacturing operations in Texas.
Bristol Myers Squibb said the investment will expand its domestic manufacturing capabilities and strengthen its pharmaceutical supply chain while supporting future production across multiple therapeutic modalities.
